

Executive Corridor  
Darlington Memorial Hospital  
Hollyhurst Road  
Darlington  
DL3 6HX  
Switchboard Tel: 01325 38 0100  
Foundation Trust Office: 01325 74 3625  
Corporate Records Office: 01325 74 3700

Request for Information Reference: 10.20.07

Email: cdda-tr.cddftfoi@nhs.net

Email only

11 November 2020

## **Freedom of Information Act 2000 – Request for Information**

Thank you for submitting a request for information which we received on 5<sup>th</sup> October 2020 in relation to County Durham and Darlington NHS Foundation Trust (the Trust). Your request has been processed under the provisions of the Freedom of Information Act 2000 and I am now able to provide you with a response.

Firstly please accept my apologies for the time taken to respond. Your request was in relation to intra-vitreous injections/ implants and I am providing the following information in response to your specific questions:

**1. Within your Trust how many intra-vitreous injections/ implants of each of the following drugs have been used in the four-month period from May-August 2020:**

- **Aflibercept - 1588**
- **Bevacizumab - 35**
- **Brolucizumab - not used at this trust**
- **Dexamethasone - 12**
- **Fluocinolone - 1**
- **Ranibizumab -155**

**2. If your Trust is able to identify intra-vitreous injections/ implants by eye condition, please provide the number of injections/implants used from May-August 2020, for each of the following conditions:**

**Wet Age Related Macular Degeneration (wAMD)**

- **Aflibercept - 1134**
- **Bevacizumab - 5**
- **Brolucizumab - not used at this trust**
- **Dexamethasone -1**
- **Fluocinolone - 0**

- **Ranibizumab -96**

**Diabetic Macular Oedema (DMO)**

- **Aflibercept - 208**
- **Bevacizumab - 12**
- **Dexamethasone - 1**
- **Fluocinolone - 0**
- **Ranibizumab - 12**

**Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)**

- **Aflibercept - 167**
- **Bevacizumab -2**
- **Dexamethasone - 2**
- **Fluocinolone - 0**
- **Ranibizumab -37**

**Visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV)**

- **Aflibercept - 9**
- **Bevacizumab -0**
- **Dexamethasone - 0**
- **Fluocinolone - 0**
- **Ranibizumab - 5**

**3. Within your Trust how many patients have been treated for Uveitis in the four-month period from May to August 2020 with the following:**

- **Dexamethasone intra-vitreous implants - 1**
- **Any other anti-VEGF injections/implants - 0**
- **Infliximab - 0**
- **Adalimumab - 0**
- **Toclizumab -0**

In line with the Information Commissioner's directive on the disclosure of information under the Freedom of Information Act 2000 your request will form part of our disclosure log on the Trust's website. However please be assured that we anonymise all responses prior to adding them to the disclosure log.

I hope that this response has provided you with the information you had. If you have any queries or wish to discuss the information supplied, please do not hesitate to contact me by telephone or in writing. If however, you are dissatisfied with the way in

which your request has been handled and would like an internal review, you will need to contact me in writing at the above address or via [cdda-tr.cddffoi@nhs](mailto:cdda-tr.cddffoi@nhs).

If you remain dissatisfied with our response following an internal review you have the right to appeal to The Information Commissioner at Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. More information is available on their website; [www.ico.gov.uk](http://www.ico.gov.uk).

Yours sincerely



**Joanna Tyrrell**  
**Freedom of Information Officer**